A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

ClinicalTrials.gov ID

NCT07808060

Lead Sponsor

Eli Lilly and CompanyINDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

34Estimated

Last Update Posted

Sep 8, 2026Actual

Start Date

Sep 2026Estimated

Primary Completion Date

Jun 2027Estimated

Completion Date

Jun 2027Estimated

Official Title

A Phase 1, Open-Label Study to Evaluate the Effect of Eloralintide on the Pharmacokinetics of the Combined Oral Contraceptive Levonorgestrel-Ethinyl Estradiol in Female Participants With Obesity or Overweight

Brief Summary

The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Research Unit (CRU), each lasting between 6 - 8 nights.

• Obesity
• Overweight

• Eloralintide
• Combined oral contraceptive

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

Female

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• Are individuals AFAB who are individuals of childbearing potential using non-hormonal methods of contraception, or individuals not of childbearing potential.
• Have safety laboratory test results within normal reference range for the population or investigative site.
• Have a body mass index (BMI) within the range of 27.0 to 35.0 kilograms per square meter (kg/m²), inclusive.
• Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.

Exclusion Criteria:

• Have a history or presence of contraindications to the Combined Oral Contraceptive (COC) tablet including thrombosis and the history of any thromboembolic disease, recurrent jaundice, acute or chronic liver disease, hormonally-induced migraines, undiagnosed vaginal bleeding, significant hyperlipidemia, and mammary, endometrial, or hepatic carcinoma (known or suspected).
• Have known risks of arterial or venous thrombotic diseases.
• Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
• Have a known clinically significant gastric emptying abnormality; a GI disorder that impacts GI absorption or gastric emptying; or have undergone weight loss surgery; or have had endoscopic and/or device-based therapy for obesity or device removal within the last 6 months.
• Have a history of breast, uterine or ovarian cancer any time or have any malignancy within the past 5 years with the exceptions of basal cell or squamous epithelial carcinomas of the skin, or cervical carcinoma in situ.
• Have received drugs that reduce GI motility within 1 month prior to screening.
• Have received oral contraceptives within 3 months, implanted contraceptives within 6 months, injectable contraceptives within 12 months, or topical controlled delivery contraceptives (patch) or hormonal intrauterine device within 3 months prior to the study or plan to use during the study.
• Have an estimated glomerular filtration rate (eGFR), using the Chronic Kidney Disease Epidemiology Collaboration equation (2021), less than 60.0 milliliter per minute per 1.73 square meters (mL/Minute/1.73m²).
• Are pregnant or intend to become pregnant or to breastfeed during the study.

Primary Purpose

Basic Science

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Eli Lilly and CompanyINDUSTRY

866-429-3700

• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

  NCT07738614

  RecruitingInterventionalPhase 1Updated Aug 20, 2026
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  NCT07321886

  RecruitingInterventionalPhase 3Updated Aug 21, 2026
• A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

  NCT07665879

  RecruitingInterventionalPhase 1Updated Jul 16, 2026
• A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

  NCT06916065

  CompletedInterventionalPhase 1Updated Jan 30, 2026
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  NCT07282600

  RecruitingInterventionalPhase 3Updated Sep 8, 2026
• A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

  NCT06916091

  CompletedInterventionalPhase 1Updated Nov 19, 2025